iShares iBoxx $ High Yield Corporate Bond ETF vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.22 (market cap $17.89B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 3.3× iShares iBoxx $ High Yield Corporate Bond ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| HYG | TAK | |
|---|---|---|
Market Cap | $17.89B | $58.74B |
Volume | 44,866,592 | 3,110,994 |
Sector | Fixed Income | Health |
52-Week High | $81.28 | $19.05 |
52-Week Low | $76.90 | $13.23 |
Typical Hold Time | 60 Days | 1 Days |
Enterprise Value | — | $86.65B |
Dividend Yield | — | 3.33% |
Signals from Pluang's Aura AI — not financial advice
HYG trades at $77.23 with minimal daily movement (+0.06%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators suggest potential stabilization. Recent dividend payments provide consistent income, with the latest $0.38 distribution paid in August 2026. The fund faces headwinds from rising Treasury yields and bond market volatility, with key technical indicators showing mixed signals between short-term stabilization and longer-term bearish momentum.
High yield bond ETFs like HYG face pressure from rising interest rates and inflation concerns, though the fund's diversified corporate bond portfolio offers yield advantages over Treasury securities. The current environment presents both income opportunities through attractive yields and risks from potential credit deterioration if economic conditions worsen. Investors should weigh the fund's income generation against interest rate sensitivity and credit risk exposure in the current tightening cycle.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →